ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Nanocarriers in psychiatry: a comprehensive review of emerging frontiers in the management of psychiatric disorders.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric disorders are characterized by clinically significant disturbances in cognition, emotional regulation, and behavior and represent a substantial global health burden. Pharmacological management relies primarily on antidepressants, anxiolytics, antipsychotics, mood stabilizers, hypnotics, and stimulants. However, conventional therapy may be limited by unfavorable physicochemical properties, variable pharmacokinetics, suboptimal brain exposure, frequent dosing, and systemic adverse effects, which may compromise therapeutic outcomes and long-term treatment adherence. Nanocarrier-based drug delivery systems have emerged as a promising approach to address some of these limitations. By optimizing particle size, composition, morphology, and surface characteristics, nanocarriers may improve drug solubility and stability, modify pharmacokinetic and release profiles, protect therapeutic agents from degradation, and facilitate brain delivery through the blood-brain barrier-associated transport mechanisms or nose-to-brain pathways. Controlled or sustained release may additionally reduce dosing frequency and improve patients' compliance. This review critically examines organic, inorganic, and hybrid nanocarrier systems investigated for psychotropic drug delivery, with particular emphasis on brain delivery mechanisms, safety considerations, clinical translation, regulatory challenges, and emerging strategies for psychiatric nanomedicine.
Indexed as
Identifiers
42875549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.